Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study. E. Vandecasteele (Ghent, Belgium), K. Melsens (Ghent, Belgium), D. Blockmans (Leuven, Belgium), C. Carton (Ghent, Belgium), F. De Keyser (Ghent, Belgium), E. De Langhe (Leuven, Belgium), B. Lauwerys (Brussels, Belgium), Y. Piette (Ghent, Belgium), A. Vanhaecke (Ghent, Belgium), K. Verbeke (Ghent, Belgium), W. Wuyts (Leuven, Belgium), G. Brusselle (Ghent, Belgium), V. Smith (Ghent, Belgium)
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Vandecasteele (Ghent, Belgium), K. Melsens (Ghent, Belgium), D. Blockmans (Leuven, Belgium), C. Carton (Ghent, Belgium), F. De Keyser (Ghent, Belgium), E. De Langhe (Leuven, Belgium), B. Lauwerys (Brussels, Belgium), Y. Piette (Ghent, Belgium), A. Vanhaecke (Ghent, Belgium), K. Verbeke (Ghent, Belgium), W. Wuyts (Leuven, Belgium), G. Brusselle (Ghent, Belgium), V. Smith (Ghent, Belgium). Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study.. 3392
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe. Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019
PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014
Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020
Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014
Is pulmonary sarcoidosis more severe in children? A multicentric retrospective study Source: International Congress 2014 – Sarcoidosis Year: 2014
Comorbidities associated with sarcoidosis – Results from long-term observational study Source: International Congress 2014 – Sarcoidosis Year: 2014
Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial Source: International Congress 2014 – Sarcoidosis Year: 2014
Treatment dilemmas in sarcoidosis - a retrospective cohort study Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study Source: ERJ Open Res, 8 (1) 00552-2021; 10.1183/23120541.00552-2021 Year: 2022
Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial Source: International Congress 2014 – ILDs 3 Year: 2014
Plasma levels of acute phase proteins in patients from the multicenter longitudinal French Cohort in Lung Transplantation (COLT): a pilot study Source: Virtual Congress 2020 – Treatments and biomarkers for lung allograft function and outcome Year: 2020
Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014
Mortality in sarcoidosis, results from one centre, long term observational study Source: International Congress 2014 – Sarcoidosis Year: 2014
Idiopathic Pulmonary Fibrosis based on disease behavior: Workshop summary of a Japanese multicenter study Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019
Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study Source: Eur Respir J, 56 (3) 2000767; 10.1183/13993003.00767-2020 Year: 2020
A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014
Risk factors for idiopathic pulmonary fibrosis in Southern Europe: A case-control study Source: Annual Congress 2013 –Occupational respiratory diseases: asthma, silicosis and asbestosis Year: 2013
Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020